Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.8K
Recombinant DNA01:09

Recombinant DNA

105.5K
Overview
105.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous Affinity Maturation and Liability Removal from Antibodies.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Discovering novel therapeutic V<sub>H</sub>Hs for emerging viruses: perspectives from VEEV selection strategies.

Frontiers in immunology·2026
Same author

Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.

Vaccine·2026
Same author

Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study.

BMJ neurology open·2026
Same author

Combining Yeast Display and Bacterial Genomic Library for the Unbiased Isolation of Novel Polysaccharide-Binding Peptides.

International journal of molecular sciences·2026
Same author

TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

Blood·2026
Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026
Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026
Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026
Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026
Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026
Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

44.3K

Recombinant renewable polyclonal antibodies.

Fortunato Ferrara1, Sara D'Angelo, Tiziano Gaiotto

  • 1a New Mexico Consortium ; Los Alamos , NM USA.

Mabs
|December 23, 2014
PubMed
Summary
This summary is machine-generated.

Researchers developed a method to create high-quality recombinant polyclonal antibodies using phage and yeast display. These renewable antibodies are highly specific, can be amplified extensively, and offer a superior alternative to traditional polyclonal antibody mixtures.

Keywords:
CTBP, C-terminal binding protein; ELISA, enzyme linked immunosorbant assay; HCDR3, Heavy chain complementarity determining region 3; HPA, Human Protein Atlas; scFv, single chain Fv; PrESTs, Protein epitope signature tag; rrpAbs, recombinant renewable polyantibody validationphage displaypolyclonal recombinant antibodiesyeast display

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.6K
Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.6K

Related Experiment Videos

Last Updated: Apr 19, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

44.3K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.6K
Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.6K

Area of Science:

  • Biotechnology
  • Immunology
  • Molecular Biology

Background:

  • Traditional polyclonal antibody mixtures contain many non-target-specific antibodies, leading to polyreactivity.
  • Existing polyclonal antibodies are limited resources and cannot be easily amplified without losing functionality or representation.

Purpose of the Study:

  • To develop a method for generating high-quality, renewable recombinant polyclonal antibodies in vitro.
  • To demonstrate the ability to amplify these antibodies extensively without loss of function or diversity.
  • To show the selective amplification of antibodies targeting specific epitopes and elimination of non-specific antibodies.

Main Methods:

  • Utilized a combination of phage and yeast display technologies for in vitro antibody generation.
  • Tested the protocol on nine different protein targets to assess specificity and diversity.
  • Demonstrated the amplification of recombinant polyclonal antibodies over one hundred million-fold.

Main Results:

  • Successfully generated high-quality recombinant polyclonal antibodies directed towards specific targets.
  • Achieved selective amplification of antibodies recognizing target-specific epitopes while eliminating those recognizing common epitopes.
  • Demonstrated extensive amplification (over 100 million-fold) without loss of antibody representation or functionality.
  • Confirmed the renewable nature and high throughput generation of these antibodies.

Conclusions:

  • Recombinant polyclonal antibodies generated via phage and yeast display offer a renewable and highly specific alternative to traditional polyclonal antibodies.
  • This in vitro approach allows for precise control over antibody specificity and extensive amplification, overcoming limitations of traditional methods.
  • The technology has the potential to create highly specific, renewable antibody libraries against all human gene products for various applications.